Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics
Executive Summary
Legislation headed to President Trump would also ban pharmacy "gag" clauses.
You may also be interested in...
Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?
AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.
Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?
AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.
Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple
US Congress wants to prohibit contracts that prevent pharmacists from alerting customers to opportunities to save money by paying out of pocket. Legislation is moving rapidly, but once again, a simple fix to a drug pricing issue may have unintended consequences.